Title:
Engineering Human Stem Cells for Treating Cardiac Diseases

dc.contributor.author Lian, Xiaojun L.
dc.contributor.corporatename Georgia Institute of Technology. Institute for Electronics and Nanotechnology en_US
dc.contributor.corporatename Pennsylvania State University. Department of Biomedical Engineering en_US
dc.contributor.corporatename Pennsylvania State University. Department of Biology en_US
dc.contributor.corporatename Huck Institutes of the Life Sciences en_US
dc.date.accessioned 2020-11-05T17:11:01Z
dc.date.available 2020-11-05T17:11:01Z
dc.date.issued 2020-10-27
dc.description Presented online October 27, 2020, 12:00 p.m.-1:00 p.m. at Nano@Tech Virtual Fall 2020. en_US
dc.description Hosted by: Graduates In Nanotechnology (GIN) Research Group at Georgia Tech. en_US
dc.description Dr. Lance Lian received his PhD in Chemical engineering from University of Wisconsin-Madison in 2012. During his PhD, Dr. Lian's “Cardiomyocyte Differentiation from Human Pluripotent Stem Cells” paper was awarded the best biomedical paper in PNAS and the Cozzarelli Prize of the National Academy of Sciences in 2012. Dr. Lian did his postdoc training at Harvard University and Karolinska Institute for stem cell research. After joining Penn State in 2015, Dr. Lian developed the world’s first pancreatic cell differentiation method from stem cells for treating diabetes with only small molecules, which makes this production much more cost-effective and efficient. en_US
dc.description Runtime: 46:21 minutes en_US
dc.description.abstract Human pluripotent stem cells (hPSCs) offer the potential to generate large numbers of functional cardiomyocytes from clonal and patient-specific cell sources. Here we show that temporal modulation of Wnt signaling is both essential and sufficient for efficient cardiac induction in hPSCs under defined, growth factor-free conditions. shRNA knockdown of β-catenin during the initial stage of hPSC differentiation fully blocked cardiomyocyte specification, whereas glycogen synthase kinase 3 inhibition at this point enhanced cardiomyocyte generation. Furthermore, sequential treatment of hPSCs with glycogen synthase kinase 3 inhibitors followed by inducible expression of β-catenin shRNA or chemical inhibitors of Wnt signaling produced a high yield of virtually (up to 98%) pure functional human cardiomyocytes from multiple hPSC lines. The robust ability to generate functional cardiomyocytes under defined, growth factor-free conditions solely by genetic or chemically mediated manipulation of a single developmental pathway should facilitate scalable production of cardiac cells suitable for research and regenerative applications. en_US
dc.format.extent 46:21 minutes
dc.identifier.uri http://hdl.handle.net/1853/63812
dc.language.iso en_US en_US
dc.publisher Georgia Institute of Technology en_US
dc.relation.ispartofseries Nano@Tech Lecture Series
dc.subject Cardiac diseases en_US
dc.subject Stem cells en_US
dc.title Engineering Human Stem Cells for Treating Cardiac Diseases en_US
dc.type Moving Image
dc.type.genre Lecture
dspace.entity.type Publication
local.contributor.corporatename Institute for Electronics and Nanotechnology (IEN)
local.relation.ispartofseries Nano@Tech Lecture Series
relation.isOrgUnitOfPublication 5d316582-08fe-42e1-82e3-9f3b79dd6dae
relation.isSeriesOfPublication accfbba8-246e-4389-8087-f838de8956cf
Files
Original bundle
Now showing 1 - 4 of 4
No Thumbnail Available
Name:
lian.mp4
Size:
177.87 MB
Format:
MP4 Video file
Description:
Download Video
No Thumbnail Available
Name:
lian_videostream.html
Size:
1.32 KB
Format:
Hypertext Markup Language
Description:
Streaming Video
No Thumbnail Available
Name:
transcript.txt
Size:
32.42 KB
Format:
Plain Text
Description:
Transcription Text
Thumbnail Image
Name:
thumbnail.jpg
Size:
44.73 KB
Format:
Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.13 KB
Format:
Item-specific license agreed upon to submission
Description:
Collections